Rangering i aksjer
#35468
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
Aksjekurs
$0.14942078
Sist synkronisert: 2025-05-15
Handel Medigene AG (MDG1)
Pris MDG1 pris med markedsverdi på B
Markedsverdi av Medigene AG(MDG1)
Markedsverdi: $3.86M
Per August 2026 har Medigene AG en markedsverdi på $3.86M. Dette gjør Medigene AG til det 35468th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Medigene AG fra 2000 til 2026
MDG1 sammenlignet med topp 5 mest populære stocks
| Pris på MDG1 |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.452T
|
+141,055,068.21%
|
|
|
|
|
$4.490T
|
+116,169,363.61%
|
|
|
|
|
$4.162T
|
+107,693,088.99%
|
|
|
|
|
$3.676T
|
+95,117,229.79%
|
|
|
|
|
$2.833T
|
+73,298,689.27%
|
